CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
Cannabidiol 600mgdrug
Likely dose
Cannabidiol 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04192370
NCT04192370Phase 2Completed
CompareCT.gov

A Single-arm, Open-label Feasibility Pilot of Cannabidiol as an Adjunct to Sublingual Buprenorphine on Cue-induced Cravings Among Individuals With Opioid Use Disorder

Brigham and Women's Hospital·interventional·Posted Dec 10, 2019·Updated May 18, 2023

In Brief

A Phase 2 clinical trial evaluating Cannabidiol 600mg for Opioid-use Disorder. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid-use Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 10, 2019
Enrollment StartAug 3, 2020
Primary CompletionDec 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.6 years ago

Interventions

Cannabidiol 600mgdrug

All subjects will receive 600mg of oral cannabidiol for 3 days in an open-label fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL, and the drug will be procured by the Brigham and Women's Hospital (BWH) Investigational Drug Services (IDS) pharmacy. The first dose will be administered at the BWH Center for Clinical Investigation, while doses 2 and 3 will be self-administrated at home. The CBD will be repacked in pre-drawn syringes for the subjects to self-administer at home.